血清HMGB1与COPD急性加重期患者炎性指标肺功能参数之间的相关性

doi:10.3969/j.issn.1006-6233.2023.10.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1214 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the correlation of serum high mobility group protein 1 (HMGB1) with inflammatory indicators and pulmonary function parameters in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods: A total of 104 patients with AECOPD who were treated in the hospital from January 2020 to June 2022 were selected and included in AECOPD group, and another 104 patients with stable chronic obstructive pulmonary disease (COPD) were enrolled as COPD group. 104 healthy subjects with physical examination during the same time period were included in healthy control group. The levels of peripheral blood related indicators [HMGB1, hypoxia-inducible factor-1α (HIF-1α), white blood cell count (WBC)] and serum inflammatory factors [interleukin-6 (IL-6), C-reactive protein (CRP), procalcitonin (PCT)] and pulmonary function parameters [6-minute walk distance (6MWD), pulmonary artery pressure, partial pressure of carbon dioxide (PaCO₂), partial pressure of oxygen (PaO₂)] were compared among the groups at admission. The relationship between serum HMGB1 and the above inflammatory indicators and pulmonary function parameters was analyzed. Results: The levels of serum HMGB1, HIF-1α, IL-6, CRP, PCT and WBC in the three groups at admission were manifested as AECOPD group>COPD group> healthy control group (P<0.05). The 6MWD and PaO₂ at admission were shown as AECOPD group<COPD group< healthy control group (P<0.05). The pulmonary artery pressure and PaCO₂ of the three groups at admission showed AECOPD group>COPD group>healthy control group (P<0.05). Pearson correlation analysis showed that serum HMGB1 level at admission was positively correlated with IL-6, CRP and pulmonary artery pressure in patients with AECOPD (r=0.566, 0.287, 0.230, all P<0.05), and was negatively correlated with PaO₂ (r=-0.212, P<0.05). Conclusion: Compared with patients with stable COPD and healthy subjects, serum HMGB1 level in patients with AECOPD is abnormally increased, and serum HMGB1 is closely related to IL-6, CRP, pulmonary artery pressure and PaO₂.

Key words： Chronic obstructive pulmonary disease Acute exacerbation Serum high mobility group protein 1 Pulmonary function Correlation

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2023.10.012 OR http://www.hbyxzzs.cn/EN/Y2023/V29/I10/1649

[1] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组,中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会.慢性阻塞性肺疾病诊治指南(2021年修订版)[J].中华结核和呼吸杂志,2021,44(3):170-205.
[2] Yang K,Fan M,Wang X,et al.Lactate promotes macrophage HMGB1 lactylation,acetylation,and exosomal release in polymicrobial sepsis[J].Cell Death Differ,2022,29(1):133-146.
[3] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.慢性阻塞性肺疾病基层诊疗指南(2018年)[J].中华全科医师杂志,2018,17(11):15.
[4] Pouwels SD,Hesse L,Wu X,et al.LL-37 and HMGB1 induce alveolar damage and reduce lung tissue regeneration via RAGE[J].Am J Physiol Lung Cell Mol Physiol,2021,321(4):641-652.
[5] Lin SH,He YP,Lian JJ,et al.Procalcitonin kinetics to guide sequential invasive-noninvasive mechanical ventilation weaning in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure:procalcitonin's adjunct role[J].Libyan Med,2021,16(1):1961382.
[6] 邓爱兵,宋健,王静,等.肺CT联合降钙素原、C反应蛋白检测对COPDⅡ型呼吸衰竭疗效、预后评估的临床价值[J].临床和实验医学杂志,2021,20(2):161-165.
[7] Francis NA,Gillespie D,White P,et al.C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease:the PACE RCT[J].Health Technol Assess,2020,24(15):1-108.
[8] Shukla SD,Walters EH,Simpson JL,et al.Hypoxia-inducible factor and bacterial infections in chronic obstructive pulmonary disease[J].Respirology,2020,25(1):53-63.
[9] 贺孟君,张家艳,李燕舞,等.血清SDC-1、HIF-1α、PGRN与AECOPD患者肺功能及预后恢复的相关性分析[J].标记免疫分析与临床,2021,28(6):977-982.
[10] Kovacs G,Avian A,Bachmaier G,et al.Severe pulmonary hypertension in COPD:impact on survival and diagnostic approach[J].Chest,2022,162(1):202-212.
[11] 傅正,苏晋豫,白志余.PaO₂、PaCO₂、SaO₂对呼吸衰竭病人病情发生发展的影响[J].内蒙古医科大学学报,2020,42(6):623-625.
[12] Huang X,Tan X,Liang Y,et al.Differential DAMP release was observed in the sputum of COPD,asthma and asthma-COPD overlap (ACO) patients[J].Sci Rep,2019,9(1):19241.